Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

Advances in Stem Cell Therapy Karim Nayernia Professor of Human Genetics & Stem Cell Biology.

Advertisements

Jasna Marinović, M.D., Ph.D. Associate Professor Department of Physiology.

Brain Extracellular Matrix in Health and Disease

Wound Healing: A Paradigm for Regeneration

Review of Heart Regeneration by using induced Pluripotent Stem Cells and extracellular matrix protein, Agrin, in Mice and Primate hearts. Buntongyi Nit1,

Figure 2 Muscle structure

Figure 1 Current categories of resident cardiac fibroblasts

Michael Blaber Biomedical Sciences

Figure 4 The mechanistic link between the epithelial-to-mesenchymal

Figure 1 Newly discovered mechanistic pathways

Figure 8 Implanted devices for the management of heart failure

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Two approaches to therapeutic genome editing

Figure 1 Evolution of genetic concepts underlying risk of cardiovascular disease Figure 1 | Evolution of genetic concepts underlying risk of cardiovascular.

Figure 1 Energy supply–demand matching in health and heart failure

Figure 1 Mechanisms of metastatic growth in the heart

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 2 Size categorization of airborne pollutants

Nat. Rev. Cardiol. doi: /nrcardio

Reprogramming toward Heart Regeneration: Stem Cells and Beyond

Nat. Rev. Cardiol. doi: /nrcardio

Cardiac stem cell therapy: Checkered past, promising future?

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 Proposed arrhythmogenic right ventricular

Figure 10 The energy depletion hypothesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Decision tree integrating the assessment,

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Neural crest cell migration

Figure 2 Global cost of HF per capita in 2012

Figure 5 Examples of biomarker-guided trials

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Gross and histopathological characteristics of cardiac myxoma

Figure 3 Effects of cardiovascular medication on the fetus

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Developmental and alternative sources of fibroblasts

Figure 5 Bioresorbable vascular scaffold apposition and strut coverage

Figure 2 Cardiac metastases

Figure 6 The neurogenic components of angina

Figure 1 Essential features and goals of a precision medicine system

Figure 1 Statins, ezetimibe, and PCSK9 inhibitors all increase the expression of LDL receptors and reduce LDL-cholesterol levels (by percentages shown)

Commentary: Rejuvenation of “broken heart” with bioengineered gel

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Antifibrotic therapy in chronic liver disease

Figure 2 Impaired mitochondrial capacity and function in heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Matrix signals regulate valve cell phenotypes

Nat. Rev. Cardiol. doi: /nrcardio

Heart Regeneration 4.0: Matrix Medicine

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Determination of the primary site

Cardiac Stem Cell Therapy and the Promise of Heart Regeneration

Figure 1 Novel markers of increased stroke risk in AF

Figure 2 Metabolic shift in heart failure

Chapter 29 - Stem Cells and Generation of New Cells in the

Volume 26, Issue 7, Pages (July 2018)

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.218 Figure 1 2017 insights for the evolution of cardiac regenerative medicine Figure 1 | 2017 insights for the evolution of cardiac regenerative medicine. Use of regenerative therapies is supported by the demonstrated renewal capacity of the adult heart and by positive results of different products in animal models. In addition, first-generation stem cell therapeutics have been shown to be safe and modestly beneficial in humans. Important contributions published in 2017 show a more refined research approach and general maturation of the field: demonstration of the capacity of adult mammalian cardiomyocytes to dedifferentiate, proliferate, and redifferentiate2; identification of the important role of the extracellular matrix (ECM) protein agrin3; overcoming the 'one-shot' protocol paradigm4; clinical data supporting paracrine effects of stem cell therapies5; and the first global consensus document of a transnational alliance on cardiac regenerative medicine (TACTICS) with future implications for this field. These advances have challenged the main paradigms of the field medicine and have repositioned old and new biological treatments in the pipeline. Fernández-Avilés, F. (2018) Novel paradigms in the fight against heart failure Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.218